Biotek-snakken — Oktober 2024
-
Xbrane i aktiva avtalsförhandlingar kring Xdivane - fått första icke-bindande förslagen för XB003
I dag kl. 08:37 ∙ Finwire
Bioteknikbolaget Xbrane Biopharma har ingått aktiva avtalsförhandlingar avseende Xdivane och fått de första icke-bindande förslagen för XB003. Det framgår av ett pressmeddelande. -
ARCTIC BIOSCIENCE: ABG nedgraderer aksjen fra kjøp til hold og massakrerer kursmålet til NOK 2,5 (17).
-
Infant Bacterial Therapeutics har blivit inbjuden att presentera vid evenemanget "Live Biotherapeutic Products to Prevent Necrotizing Enterocolitis in Very Low Birth Weight Infants."
...Evenemanget kommer att laddas upp på https://videocast.nih.gov/PastEvents så snart en inspelning av det är tillgänglig. Inspelningen kommer att finnas på sidan fram till den 25 oktober 2025.
-
FDA Meetings, Conferences and Workshops
-
Ascelia Pharma presenterar Late Breaking Abstract av SPARKLE-data vid American Society of Nephrology Kidney Week Congress 2024
Ascelia Pharma Presents Late-Breaking Abstract on SPARKLE Data at the American Society of Nephrology Kidney Week Congress 2024 – ASCELIA
Ascelia Pharma AB (publ) (ticker: ACE), a biotech focused on improving the life of people living with rare cancer conditions, today announce ...
(www.ascelia.com)
.. The presentation will be held on October 24, 2024, from 10:00 AM to 12:00 PM, and will be part of the Late-Breaking Science Posters session. ..
-
Selskabspræsentation: Mød Cessatech på tirsdag.
Webinarinfo
Dato:
29.10.2024
Tid:
16:00
Sted:
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind